The trademark TERA° was filed by ELEVEN THERAPEUTICS LTD, a corporation established under the laws of the State of Israel (the "Applicant"). The application was published for oppositions on October 16, 2022, and received undefined oppositions.
Opposition Proceedings
There are undefined Oppositions claimed against trademark.
The first opposition filed on January 16, 2023 by Teva Pharmaceutical Industries Ltd. on (a) Likelihood of confusion, (b) Unfair advantage and detriment to distinctiveness or repute. the opponent was represented by D YOUNG & CO LLP and its proceedings were handled in English The second opposition filed on January 16, 2023 by IGENOMIX S.L. on Likelihood of confusion. the opponent was represented by GARRIGUES IP, S.L.P and its proceedings were handled in English
The application was filed in English, and English was also language of all opposition proceedings (German was selected as the second language).
Goods And Services
The mark was filed in class 5 with following description of goods:
Medical diagnostic reagents
Reagents for use in diagnostic tests for medical purposes
Reagents for in-vitro laboratory use for medical purposes
None of the aforesaid goods for the treatment of human infertility, reproductive medicine, embryo transfer and the treatment of sterility via assisted reproduction techniques.
The mark was filed in class 42 with following description of goods:
Science and technology services
Evaluation of product development
Pharmaceutical research and development, namely provision of tools and methods to support pharmaceutical research and development
Product research and development
Biochemical research and development
Research laboratories
Research of pharmaceuticals, namely provision of tools and methods for the discovery and optimization of pharmaceuticals
Scientific research and analysis
Biological research, clinical research and medical research
DNA screening for scientific research purposes
All the aforementioned to be used as tools and methods for research and development purposes only, not to be utilized for services related to final medical products of any kind or for direct to consumer marketing or distribution purposes
All the mentioned services not related to the treatment of human infertility, reproductive medicine, embryo transfer and the treatment of sterility via assisted reproduction techniques.